GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (NAS:PGEN) » Definitions » 5-Day RSI

Precigen (Precigen) 5-Day RSI : 55.90 (As of May. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Precigen 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-05-15), Precigen's 5-Day RSI is 55.90.

The industry rank for Precigen's 5-Day RSI or its related term are showing as below:

PGEN's 5-Day RSI is ranked worse than
63.17% of 1572 companies
in the Biotechnology industry
Industry Median: 49.07 vs PGEN: 55.90

Competitive Comparison of Precigen's 5-Day RSI

For the Biotechnology subindustry, Precigen's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precigen's 5-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precigen's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where Precigen's 5-Day RSI falls into.



Precigen  (NAS:PGEN) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Precigen  (NAS:PGEN) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Precigen 5-Day RSI Related Terms

Thank you for viewing the detailed overview of Precigen's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Precigen (Precigen) Business Description

Traded in Other Exchanges
Address
20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Executives
Jeffrey B Kindler director 35 E. 62ND ST, NEW YORK NY 10065
Randal J Kirk director, 10 percent owner, officer: Chief Executive Officer 1881 GROVE AVENUE, RADFORD VA 24141
Dean J Mitchell director C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Helen Sabzevari director, officer: President and CEO 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Rutul R Shah officer: Chief Operating Officer C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Harry Jr. Thomasian officer: Chief Financial Officer C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD 20876
Jeffrey Thomas Perez officer: SVP, IP Affairs 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Donald P. Lehr officer: Chief Legal Officer 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Steven Frank director 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Vinita D Gupta director 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Robert B Shapiro director 155 WEST BURTON PLACE, #2, CHICAGO IL 60610
Cesar L Alvarez director C/O PEDIATRIX MEDICAL GROUP, LEGAL DEPT 1301- CONCORD TERRACE, SUNRISE FL 33323
James S Turley director 9 MUIRFIELD LANE, SAINT LOUIS MO 63141
Ares Trading S.a. 10 percent owner ZONE INDUSTRIELLE DE L'OURIETTAZ, AUBONNE V8 1170